LivaNova PLC

LivaNova PLC is a global medical technology company dedicated to developing innovative solutions for neurological and cardiac conditions. Formed in 2015 through the merger of Cyberonics, Inc. and Sorin S.p.A., the company's mission is to provide hope for patients and their families by delivering life-changing improvements for both the "Head and Heart." Its legal headquarters are located in London, UK, with operational centers in the United States and Italy.

The company primarily operates through two segments: Neuromodulation and Cardiopulmonary. The Neuromodulation segment offers the VNS Therapy System for drug-resistant epilepsy and difficult-to-treat depression, and is developing the aura6000 system for obstructive sleep apnea. The Cardiopulmonary segment provides heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, and cannulae for cardiac surgery and extracorporeal circulation, including the Essenz Perfusion System.

Recent notable developments include the appointment of Vladimir Makatsaria as CEO in March 2024, and Stefano Folli as incoming President, Cardiopulmonary, effective June 1, 2026. LivaNova has also recently announced positive results from its OSPREY Study for Obstructive Sleep Apnea, demonstrating an 84.5% cumulative response rate with PolySync Programming, and received U.S. FDA Premarket Approval for its aura6000 System for moderate to severe obstructive sleep apnea. The company continues to position itself as a market leader in medical technology.